Najat Khan, PhD, unpacks realistic timelines for AI-based drugs to make clinical impact and her priorities for Recursion as incoming CEO.

REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden ...

Materials informatics combines data analytics and engineering design, streamlining material development and enhancing ...

The Atom and the Algorithm: Nuclear Energy and AI are Converging to Shape the Future Writers and futurists have long echoed Alvin and Heidi Toffler’s idea that “the future arrives too fast…and in the ...

But there’s a big problem — DeepSeek does not appear to have conducted any predeployment safety testing. There is no mention ...

Adam Hayes, Ph.D., CFA, is a financial writer with 15+ years Wall Street experience as a derivatives trader. Besides his extensive derivative trading expertise, Adam is an expert in economics and ...

By David Swanson, World BEYOND War Ah, those were the days. The UN had been blocked by a worldwide popular movement from approving of a war on Iraq. British Prime Minister Tony Blair had dragged the ...

Recursion Pharmaceuticals, Inc. is rated a Sell due to cash burn, Q3 net loss of $162.25M and operational trends. Learn more ...

Recursion Pharmaceuticals (RXRX) is drawing renewed attention after the appointment of Najat Khan as CEO and news of a narrowing net loss, both viewed as signals of improving execution. Investors also ...

Recursion Pharmaceuticals ( RXRX +1.91%) was in the headlines on Monday, and for the right reason. One of the biotech company ...

Recursion Pharma , which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths in the colon in patients with a rare ...